Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAES: Imlifidase in Highly Sensitized Kidney Transplant Patients
NCT05369975Phase 3Completed
- Sponsor
- Hansa Biopharma
- Start
- Apr 2022
- Primary completion
- Apr 2026
- Modality
- Therapeutic Enzymes
- Countries
- 11
01
Overview
Phase 3, open-label trial of imlifidase in end stage renal disease (ESRD) (3 arms), sponsored by Hansa Biopharma. Primary endpoint: Graft failure-free survival at 12 months. Started Apr 2022; status: completed.
02
Drugs
imlifidase
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT05369975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05369975.